Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoate | 204452-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoate
• 英文别名: Ethyl 4-[2-(2-Aminopyridine-6-yl)ethyl]benzoate；ethyl 4-[2-(6-aminopyridin-2-yl)ethyl]benzoate
• CAS: 204452-37-9
• 化学式: C₁₆H₁₈N₂O₂
• 分子量: 270.331
• InChiKey: JCEFWJJPNSIOLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoate 在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 60.0h， 生成 3-{4-[2-(2-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylamino-propionic acid
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

  摘要：

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.

  DOI：

  10.1021/jm000133v
• 作为产物：
  描述：

  ethyl 4-(trimethylsilylethynyl)benzoate 在 palladium on activated charcoal bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 100.0 ℃ 、101.33 kPa 条件下， 反应 39.0h， 生成 Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoate
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

  摘要：

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.

  DOI：

  10.1021/jm000133v

文献信息

• Integrin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06413955B1

  公开（公告）日：2002-07-02

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

  本发明涉及化合物及其衍生物，它们的合成以及它们作为维脱纳蛋白受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体αvβ3和/或αvβ5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症性关节炎，癌症和转移性肿瘤生长。
• Alpha V integrin receptor antagonists
  申请人：——

  公开号：US20020037889A1

  公开（公告）日：2002-03-28

  The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

  本发明涉及新型咪唑烷酮衍生物及其合成，以及它们作为αv整合素受体拮抗剂的用途。更具体地说，本发明的化合物是αvβ3和/或αvβ5整合素受体的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，炎症性关节炎，病毒性疾病，癌症和转移性肿瘤生长。
• Alpha v integrin receptor antagonists
  申请人：——

  公开号：US20020049224A1

  公开（公告）日：2002-04-25

  The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. 1

  本发明涉及通过化合物的代谢转化形成的新化合物，包含这种化合物的药物组合物，以及它们作为αvβ3整合素受体拮抗剂的用途。本发明的化合物对于抑制骨吸收、再狭窄、血管生成、糖尿病视网膜病变、黄斑变性、炎症性关节炎、癌症和转移性肿瘤生长具有用途。它们特别适用于抑制骨吸收以及治疗和预防骨质疏松症。
• &agr;v integrin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06410526B1

  公开（公告）日：2002-06-25

  The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

  本发明涉及新颖的壬酸衍生物，它们的合成以及它们作为αv整合素受体拮抗剂的用途。更具体地说，本发明的化合物是αvβ3和αvβ5整合素受体的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，炎症性关节炎，病毒性疾病，癌症和转移性肿瘤生长。
• Dibenzoxazepine alpha v integrin receptor antagonist
  申请人：——

  公开号：US20040019035A1

  公开（公告）日：2004-01-29

  The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an &agr;v integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and therefor useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, artheroscietosis, inflammatory arthritis, cancer and metastatic tumor growth.

  本发明涉及一种新颖的二苯并噁唑啉衍生物，其合成及其用作αv整合素受体拮抗剂。更具体地说，本发明的化合物是αvβ3和αvβ5整合素受体的拮抗剂，因此可用于抑制骨吸收，治疗和/或预防骨质疏松症，并抑制血管再狭窄、糖尿病视网膜病变、黄斑变性、血管生成、动脉粥样硬化、炎症性关节炎、癌症和转移性肿瘤生长。